Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Sponsor

Liaoning Tumor Hospital & Institute (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05887726

Collaborator

(none)

Enrollment

Location

Arm

Anticipated Duration (Months)

1.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is a prospective, open-label, single-arm phase II clinical study to evaluate the safety and efficacy of zanubrutinib plus R-CHOP (ZR-CHOP) as the first-line therapy for newly diagnosed diffuse large B-cell lymphoma patients with high-risk factors.

Condition or Disease	Intervention/Treatment	Phase
Diffuse Large B Cell Lymphoma	Drug: Zanubrutinib Drug: Rituximab Drug: Cyclophosphamide Drug: Epirubicin Drug: Vincristine Drug: Prednisone	Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

30 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Single-arm, Prospective Clinical Study on the Antitumor Activity and Safety of Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Anticipated Study Start Date :

Jun 1, 2023

Anticipated Primary Completion Date :

Jun 1, 2024

Anticipated Study Completion Date :

Jun 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Zanubrutinib + R-CHOP	Drug: Zanubrutinib Zanubrutinib 160mg bid p.o d0-d20(21-day cycles) Drug: Rituximab Rituximab 375 mg/m2 i.v d0(21-day cycles) Drug: Cyclophosphamide Cyclophosphamide 750 mg/m2 i.v d1(21-day cycles) Drug: Epirubicin Epirubicin 75 mg/m2 i.v d1 or liposome adriamycin 35mg/m2 i.v d1(21-day cycles) Drug: Vincristine Vincristine 1.4 mg/m2 i.v d1 (2 mg max) (21-day cycles) Drug: Prednisone Prednisone 100 mg p.o d1-d5 (21-day cycles)

Arm

Intervention/Treatment

Experimental: Zanubrutinib + R-CHOP

Drug: Zanubrutinib

Zanubrutinib 160mg bid p.o d0-d20(21-day cycles)

Drug: Rituximab

Rituximab 375 mg/m2 i.v d0(21-day cycles)

Drug: Cyclophosphamide

Cyclophosphamide 750 mg/m2 i.v d1(21-day cycles)

Drug: Epirubicin

Epirubicin 75 mg/m2 i.v d1 or liposome adriamycin 35mg/m2 i.v d1(21-day cycles)

Drug: Vincristine

Vincristine 1.4 mg/m2 i.v d1 (2 mg max) (21-day cycles)

Drug: Prednisone

Prednisone 100 mg p.o d1-d5 (21-day cycles)

Outcome Measures

Primary Outcome Measures

Complete response rate（CRR） [Up to approximately 2.5 years]

Secondary Outcome Measures

Overall response rate （ORR） [Up to approximately 2.5 years]
Progression-free Survival(PFS) [Up to approximately 2.5 years]
Overall survival (OS) [Up to approximately 2.5 years]
Duration of Response [At 2 years]
Incidence of adverse event [At 2 years]
Assessment of the correlation between MYD88、CD79B、NOTCH1、BCL6、NOTCH2 or other gene abnormality and efficacy. [At 2 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Histologically confirmed DLBCL patients have one of the following risk factors(including but not limited to double expression, extranodal involvement, high ki67, bulky)；
Age ≥ 18 years old;
At least one measurable lesion (defined as lymph node lesion ≥15mm, extra-segmental lesions ≥ 10mm);
ECOG performance status 0-2;
Functions of major organs meet the following conditions: Echocardiography left ventricular ejection fraction ≥50%; Creatinine clearance ≥30 ml/min; ALT and AST≤3 times the normal range；
Hematopoietic function should meet the following conditions: Platelet count ≥50×109/L; Hemoglobin ≥ 8.0g /dL; Absolute count of neutrophil (ANC)≥1.0×109/L;
Expected survival of ≧3 months

Exclusion Criteria:

Major surgery within 4 weeks before treatment;
Severe organ dysfunction(including but not limited to complications of uncontrolled cardiovascular diseases, blood clotting disorders, connective tissue diseases, serious infectious diseases and other diseases);
Patients who cannot cooperate with treatment or follow-up on time.
Pregnant or lactating females;
any uncontrolled active systemic infection requiring intravenous (IV) antibiotics;
There was a history of other active malignant diseases within the 2 years prior to study entry, except for: (1) adequately treated cervical carcinoma in situ; (2) local skin basal cell carcinoma or squamous cell carcinoma; (3) previous malignant disease that is under control and has undergone local radical treatment (surgical or other forms).
History of severe hemorrhagic disorders, such as hemophilia A, hemophilia B, von Willebrand's disease, or spontaneous bleeding requiring blood transfusion or other medical intervention
Human immunodeficiency virus (HIV) infection or the following serological status reflecting the presence of active hepatitis B or C virus infection: a. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) are present. Patients who are HBCAB-positive, HBsAg negative, have no hepatitis b virus (HBV) DNA (< 20 IU/mL), and agree to be monitored for HBV virus reactivation can be enrolled. Antibodies to the hepatitis C virus (HCV) are present. HCV antibody-positive patients with no HCV RNA detected could be included in the group.
The presence of any life-threatening disease, medical condition, or organ system dysfunction that the investigator believes may affect the subject's safety or pose a risk to the study.
The researchers think it is not suitable to participate in this experiment.